SecBot SecBot

TYRA

Tyra Biosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001863127 Biotech & Drug Discovery
$20.02 +0.26 (+1.32%)
Nov 13 4:00 PM ET · prev $19.76
Market cap
$1.4B
Small cap
Consensus
Buy
90% Buy or better · 21 analysts
Median target
$50.00
+150% · range $27.00–59.00
1 year
+25.9%
from $15.90 · Nov 17
30 days
+3.5%
from $19.34
52-week range
$15.90–39.61
−49% from high · low Nov 17
Avg volume 20D
627.7K
shares / day
Short interest
9.90M
≈14.4% of shares · +4.3%
Days to cover
15.3
at average volume
Insider net
+$199.2M
2 buyers · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 2 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/6

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $200.0M at an average $22.03. 2 insiders sold $791.5K. Price is 9% below their cost.

  • InstitutionsMIXED

    Q3 2026: 15 added (0 new), 15 trimmed or exited.

  • AnalystsBULLISH

    19 of 21 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +4.3% to 9.90M shares. 15.3 days to cover, ≈14.4% of shares.

  • TrendRANGE

    8% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
FRANKLIN TEMPLETON INCDOUBLED840,534$18.1M
DIMENSIONAL FUND ADVISORS LPADD328,962$7.2M
VANGUARD FIDUCIARY TRUST COADD301,739$6.6M
MORGAN STANLEYTRIM206,966$4.5M
UBS Group AGADD177,804$3.9M
Walleye Capital LLCTRIM95,576$2.1M
Jump Financial, LLCTRIM84,657$1.9M
ALPS ADVISORS INCADD79,051$1.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 90% rate it Buy or better
Strong Buy9Buy10Hold2Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +150%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Nov 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 22, 2026Oppenheimer
REITERATE
REITERATEOutperform
Sep 22, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 10, 2026Wedbush
REITERATE
REITERATEOutperform
Sep 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$200.0M
bought · 2 insiders
$791.5K
sold · 2 insiders
−9.1%
vs their $22.03 cost
DateInsiderTypeValue
Sep 15, 2026
Rueb Yuliya
Vice President, Finance (PAO)
Sep 15, 2026
AWARD$26.7K
Sep 15, 2026
Harris Todd
President and CEO
Sep 15, 2026
AWARD$7.9K
Sep 15, 2026
Fuhrman Alan
Chief Financial Officer
Sep 15, 2026
AWARD$8.7K
Sep 15, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
Sep 15, 2026
BUY$200.0M
Sep 9, 2026
Verjee Rehan
Director
Sep 9, 2026
BUY$20.0K
May 28, 2026
Gulfo Adele M.
Director
May 28, 2026
AWARD13,160 sh
May 28, 2026
MORE ROBERT J
Director
May 28, 2026
AWARD13,160 sh
May 28, 2026
Rothenberg Stephen Michael
Director
May 28, 2026
AWARD13,160 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
9,901,757
shares short
+4.3%
vs prior settlement
15.3
days to cover
≈14.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
Tyra Biosciences reported Q3 2026 net loss of $51.1M, wider than the $29.9M loss in Q3 2025, driven by increased R&D…
8-K · Impact 4/10
Nov 6, 2026 Earnings calendar
TYRA Q3 2026 Earnings Scheduled · 2026-11-06
Oct 27, 2026 SEC
BlackRock, Inc. filed an amendment to its Schedule 13G for Tyra Biosciences, reporting a 4.8% beneficial ownership…
SC 13G/A · Impact 3/10
Sep 30, 2026 Inst.
FRANKLIN TEMPLETON INC · DOUBLED
840,534 shares ($18.1M)
Sep 30, 2026 Inst.
DIMENSIONAL FUND ADVISORS LP · ADD
328,962 shares ($7.2M)
Sep 21, 2026 SEC
Biotechnology Value Fund (BVF) and related entities filed a Schedule 13G on September 21, 2026, disclosing a passive…
SC 13G · Impact 4/10
Sep 15, 2026 Insider
Rueb Yuliya was granted 2,925 shares
Vice President, Finance (PAO) @ $9.13 ($26.7K)
Sep 15, 2026 Insider
Harris Todd was granted 864 shares
President and CEO @ $9.13 ($7.9K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 6, 2026
Earnings date
TYRA Q3 2026 Earnings Scheduled · 2026-11-06
Nov 5, 2026
Press release
Tyra Biosciences to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 5, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing…
Nov 3, 2026
Earnings date
TYRA Q3 2026 Earnings Scheduled · 2026-11-03
Sep 17, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the…
Sep 10, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the…

SecBot reports

13 filings · 2 bullish · 2 bearish · 1 mixed · 8 neutral
All TYRA filing & press-release reports (13)